MCID: SVR005
MIFTS: 50

Severe Pre-Eclampsia

Categories: Cardiovascular diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Severe Pre-Eclampsia

MalaCards integrated aliases for Severe Pre-Eclampsia:

Name: Severe Pre-Eclampsia 12 55 15 72 33
Severe Preeclampsia 12 15
Severe Pre-Eclampsia, Antepartum Condition or Complication 72
Severe Pre-Eclampsia, Postpartum Condition or Complication 72
Severe Pre-Eclampsia, with Delivery 12
Antepartum Severe Pre-Eclampsia 12
Postpartum Severe Pre-Eclampsia 12
Severe Toxemia 72

Classifications:



External Ids:

Disease Ontology 12 DOID:13129
ICD9CM 35 642.50
ICD10 33 O14.1
UMLS 72 C0156669 C0156672 C0156673 more

Summaries for Severe Pre-Eclampsia

Disease Ontology : 12 A pre-eclampsia that has symptom at least one of the following: SBP of 160mm HG or higher or DPB of 110mm HG or higher on 2 occasions at least 6 hours apart, proteinuria more than 5g in a 24-hour collection, pulmonary edema or cyanosis, oliguria, persistent headaches, epigastric pain and/or impaired liver function, thrombocytopenia, oligohydramnios, decreased fetal growth or placental abruption.

MalaCards based summary : Severe Pre-Eclampsia, also known as severe preeclampsia, is related to eclampsia and mild pre-eclampsia, and has symptoms including at least one of the following An important gene associated with Severe Pre-Eclampsia is HLA-G (Major Histocompatibility Complex, Class I, G), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Dalteparin and Ephedrine have been mentioned in the context of this disorder. Affiliated tissues include placenta, liver and endothelial, and related phenotypes are homeostasis/metabolism and cardiovascular system

Related Diseases for Severe Pre-Eclampsia

Diseases in the Eclampsia family:

Pre-Eclampsia Severe Pre-Eclampsia

Diseases related to Severe Pre-Eclampsia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 257)
# Related Disease Score Top Affiliating Genes
1 eclampsia 31.0 SERPINC1 PGF LGALS13 HLA-G ALB
2 mild pre-eclampsia 31.0 VCAM1 PGF LEP
3 antiphospholipid syndrome 30.9 VCAM1 SERPINC1 F5 APOH
4 end stage renal failure 30.5 LEP FN1 ALB
5 brain edema 30.3 VEGFA MMP9 ALB
6 placental insufficiency 30.3 VEGFA PGF LEP FGR
7 hellp syndrome 30.3 SERPINC1 PGF LGALS13 GPT F5 APOH
8 patau syndrome 30.0 PGF LGALS13
9 proteasome-associated autoinflammatory syndrome 1 30.0 VCAM1 MMP9 ALB
10 liver disease 29.8 LEPR LEP GPT ALB
11 liver cirrhosis 29.7 SERPINC1 LEP GPT ALB
12 glucose intolerance 29.7 RBP4 LEPR LEP
13 amaurosis fugax 29.6 MMP9 F5
14 homocysteinemia 29.3 SERPINC1 F5 ALB
15 thrombophilia due to thrombin defect 29.2 SERPINC1 F5 APOH
16 pre-eclampsia 29.2 VEGFA VCAM1 SERPINC1 PGF LGALS13 LEP
17 thrombophilia 29.1 SERPINC1 F5 APOH
18 placental abruption 29.1 SERPINC1 PGF F5 APOH
19 endocarditis 29.1 VCAM1 SERPINC1 APOH ALB
20 intracranial hypertension 28.9 SERPINC1 F5 APOH
21 antithrombin iii deficiency 28.8 SERPINC1 F5 APOH
22 thrombosis 28.8 SERPINC1 F5 APOH
23 thrombophilia due to activated protein c resistance 28.8 SERPINC1 F5 APOH
24 pulmonary embolism 28.7 SERPINC1 F5 APOH ALB
25 protein s deficiency 28.6 SERPINC1 F5 APOH
26 budd-chiari syndrome 28.6 SERPINC1 F5 APOH
27 placenta disease 28.2 SERPINC1 PGF F5 APOH
28 vascular disease 27.4 VEGFA VCAM1 SERPINC1 MMP9 F5 APOH
29 severe nonproliferative diabetic retinopathy 10.6 VEGFA ALB
30 angiokeratoma circumscriptum 10.5 VEGFA MMP9
31 acroosteolysis 10.5 VEGFA ALB
32 hepatic tuberculosis 10.5 GPT ALB
33 villous adenocarcinoma 10.5 MMP9 FN1
34 kwashiorkor 10.5 GPT ALB
35 adamantinous craniopharyngioma 10.4 VEGFA MMP9
36 balanitis xerotica obliterans 10.4 VEGFA APLN
37 trypanosomiasis 10.4 VCAM1 HLA-G ALB
38 protein-energy malnutrition 10.4 LEP GPT ALB
39 hepatic coma 10.4 GPT ALB
40 portal hypertension 10.4 VEGFA GPT ALB
41 sick building syndrome 10.4 VEGFA MMP9 LEP
42 thrombocytopenia 10.4
43 lipoblastoma 10.4 LEPR LEP
44 pulmonary edema 10.4
45 respiratory distress syndrome in premature infants 10.3
46 disseminated intravascular coagulation 10.3
47 newborn respiratory distress syndrome 10.3
48 acute kidney failure 10.3
49 microvascular complications of diabetes 1 10.3 VEGFA VCAM1 MMP9
50 parotitis 10.3 MMP9 ALB

Graphical network of the top 20 diseases related to Severe Pre-Eclampsia:



Diseases related to Severe Pre-Eclampsia

Symptoms & Phenotypes for Severe Pre-Eclampsia

Symptoms:

12
  • at least one of the following

MGI Mouse Phenotypes related to Severe Pre-Eclampsia:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.3 ALB APLN APOH F5 FN1 HLA-G
2 cardiovascular system MP:0005385 10.29 APLN F5 FGR FN1 LEP LEPR
3 embryo MP:0005380 10.15 APLN F5 FN1 LEP LEPR PGF
4 hematopoietic system MP:0005397 10.13 FGR FN1 HLA-G LEP LEPR MMP9
5 immune system MP:0005387 10.13 FGR FN1 HLA-G LEP LEPR MMP9
6 muscle MP:0005369 9.92 ALB APLN FN1 LEP LEPR MMP9
7 liver/biliary system MP:0005370 9.91 ALB F5 FN1 LEP LEPR SERPINC1
8 limbs/digits/tail MP:0005371 9.88 FN1 LEP LEPR MMP9 RBP4 VEGFA
9 neoplasm MP:0002006 9.8 ALB FN1 LEP LEPR MMP9 PGF
10 renal/urinary system MP:0005367 9.7 ALB LEP LEPR MMP9 RBP4 SERPINC1
11 reproductive system MP:0005389 9.56 FN1 LEP LEPR MMP9 RBP4 SERPINC1
12 vision/eye MP:0005391 9.23 APLN LEP LEPR MMP9 PGF RBP4

Drugs & Therapeutics for Severe Pre-Eclampsia

Drugs for Severe Pre-Eclampsia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dalteparin Approved Phase 4 9005-49-6
2
Ephedrine Approved Phase 4 299-42-3 9294
3
Pseudoephedrine Approved Phase 4 90-82-4 7028
4
Enoxaparin Approved Phase 4 9005-49-6 772
5
leucovorin Approved Phase 4 58-05-9 143 6006
6
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
7
Clonidine Approved Phase 4 4205-90-7 2803
8
Captopril Approved Phase 4 62571-86-2 44093
9
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
10
Azithromycin Approved Phase 4 83905-01-5 447043 55185
11
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
12 Pharmaceutical Solutions Phase 4
13 Antibodies Phase 4
14 Immunoglobulins Phase 4
15 Antibodies, Antiphospholipid Phase 4
16 Anti-Infective Agents Phase 4
17 Heparin, Low-Molecular-Weight Phase 4
18 Adrenergic alpha-2 Receptor Agonists Phase 4
19 Adrenergic Agonists Phase 4
20 Adrenergic alpha-Agonists Phase 4
21 Sympatholytics Phase 4
22 Central Nervous System Stimulants Phase 4
23 Vasoconstrictor Agents Phase 4
24 Micronutrients Phase 4
25 Trace Elements Phase 4
26 Vitamin B9 Phase 4
27 Hematinics Phase 4
28 Folate Phase 4
29 Vitamin B Complex Phase 4
30 Nutrients Phase 4
31 Natriuretic Agents Phase 4
32 diuretics Phase 4
33 Sodium Potassium Chloride Symporter Inhibitors Phase 4
34 Angiotensin-Converting Enzyme Inhibitors Phase 4
35 Iron Supplement Phase 4
36 Lactoferrin Phase 4
37 Respiratory System Agents Phase 4
38 Nasal Decongestants Phase 4
39 Anti-Asthmatic Agents Phase 4
40 Bronchodilator Agents Phase 4
41
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
42
Misoprostol Approved Phase 3 59122-46-2 5282381
43
Oxytocin Approved, Vet_approved Phase 3 50-56-6 439302 53477758
44
Carbetocin Approved, Investigational Phase 3 37025-55-1 16681432 71715
45
Digoxin Approved Phase 2, Phase 3 20830-75-5 30322 2724385
46
Nicardipine Approved, Investigational Phase 3 55985-32-5 4474
47
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
48
Titanium dioxide Approved Phase 3 13463-67-7
49
Povidone Approved Phase 3 9003-39-8
50
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311

Interventional clinical trials:

(show top 50) (show all 113)
# Name Status NCT ID Phase Drugs
1 Effectiveness Of Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia: Randomized Placebo-Controlled Clinical Trial Unknown status NCT01361425 Phase 4 methildopa;placebo
2 Postpartum Prophylaxis With Short Course Magnesium Sulfate in Severe Preeclampsia: a Randomized Clinical Trial Completed NCT01408979 Phase 4 Magnesium sulfate 12 hours;Magnesium sulfate 24 hours
3 A Randomized Open-label Study to Compare the Clinical Outcomes and Magnesium Serum Concentrations Obtained in the Treatment of Severe Preeclampsia With a Repeat Bolus Intravenous Magnesium Sulfate Regimen Administered With the Springfusor Infusion Pump to a Continuous Intravenous Magnesium Sulfate Regimen Completed NCT02091401 Phase 4 Magnesium Sulfate
4 Low Molecular Weight Heparin for Treatment of Recurrent Miscarriage With Negative Antiphospholipid Antibodies: a Randomized Controlled Trial Completed NCT01608347 Phase 4 LMWH+Folic acid;Folic Acid
5 Effectiveness of Postpartum Furosemide on Recovery Blood Pressure in Puerperal Women With Severe Preeclampsia: a Randomized Clinical Trial Completed NCT02163655 Phase 4 FUROSEMIDE;Placebo
6 Randomized Clinical Trial for Effectiveness of Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure Completed NCT01761916 Phase 4 CLONIDINE;CAPTOPRIL
7 Evaluation of Dose-response Effect of Acetylsalicylic Acid on Placental Development, Preterm Birth, Fetal Growth and Hypertension in Pregnancy in Women With Previous History of Preeclampsia Completed NCT01352234 Phase 4 Acetylsalicylic Acid 160 mg;Acetylsalicylic Acid 80 mg
8 Phase IV Study of Oral Administration of Bovine Lactoferrin (bLf) to Prevent and Cure Iron Deficiency (ID) and Iron Deficiency Anemia (IDA) Until Delivery in Hereditary Thrombophilia (HT) Affected Pregnant Women Completed NCT01221844 Phase 4 FerroGrad by Abbott
9 Prophylactic Ephedrine to Reduce Fetal Bradycardia After Combined Spinal Epidural Labor Analgesia: a Randomized Double Blind Placebo-controlled Study Completed NCT02062801 Phase 4 Ephedrine;Placebo
10 Efficacy and Safety of One Gram Versus Two Grams Intravenous Maintenance Dose of Magnesium Sulfate in Women With Severe Pre-eclampsia: a Randomized Clinical Trial. Recruiting NCT03164304 Phase 4 Magnesium Sulfate
11 Impact of Antichlamydial Treatment on the Rate of Preeclampsia Among Egyptian Primigravidae: a Randomized Controlled Trial Recruiting NCT03233880 Phase 4 Azithromycin 1gm
12 Continuation Versus Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial Not yet recruiting NCT03318211 Phase 4 Magnesium Sulfate
13 Effectiveness and Safety of 1g/Hour vs. 2g/Hour of Magnesium Sulfate Maintenance Dose for Eclampsia Prevention: Randomized Clinical Trial Terminated NCT02396030 Phase 4 Magnesium sulfate 50% - 1g/h;Magnesium sulfate 50% - 2g/h
14 Clinical Effect of Atenativ Treatment on Uterine Blood Flow and the Amount of Atenativ Needed to Maintain a Normal Antithrombin Lvels During Two Weeks in Early and Severe Preeclampsia Withdrawn NCT02278575 Phase 4 Atenativ
15 Carbetocin Versus Oxytocin for Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia: a Double Blind Randomized Controlled Trial Unknown status NCT01382732 Phase 3 Carbetocin;Oxytocin
16 Use of Sildenafil Citrate in Management of Mild Pre-eclampsia: A Randomized Controlled Trial Unknown status NCT03262961 Phase 2, Phase 3 Sildenafil 20 MG;Placebo Oral Tablet
17 Carbetocin in Preventing Postpartum Bleeding in Women With Severe Preeclampsia. Completed NCT02086994 Phase 3 misoprostol;carbetocin
18 Ibuprofen Versus Acetaminophen in Women With Severe Pre-eclampsia After Vaginal Delivery. Completed NCT01988298 Phase 2, Phase 3 Ibuprofen;Acetaminophen
19 The Best Magnesium Sulphate Protocol for Severe Pre-eclampsia : A Randomized Controlled Trial Completed NCT01846156 Phase 3 MgSO4
20 A Novel Protocol for Postpartum Magnesium Sulfate in Severe Preeclampsia When the Woman Received Less That 8 Hours Before Delivery. Six Versus Twenty-four Hours Postpartum Completed NCT02317146 Phase 2, Phase 3 Magnesium Sulfate
21 Magnesium Sulfate During the Postpartum in Women With Severe Preeclampsia Receiving Treatment for More Than 8 Hours Before Delivery. A Randomized Multicenter Clinical Trial . Completed NCT02307201 Phase 2, Phase 3 Magnesium Sulfate
22 Low Molecular Weight Heparin, Enoxaparin, to Prevent Adverse Maternal and Perinatal Outcomes in Women With Previous Severe Preeclampsia at Less Than 34 Weeks' Gestation. A Prospective Randomized Trial Completed NCT00986765 Phase 3 Lovenox® (enoxaparin);Aspegic ® (Aspirin)
23 Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy and Death in Preterm Infants (MASP-STUDY) Completed NCT01492608 Phase 3 Magnesium sulphate
24 Oral Nifedipine Versus IV Labetalol in Treatment of Severe Pre Eclampsia in Pregnancy Recruiting NCT03325348 Phase 2, Phase 3 Nifedipine 10 mg;Labetalol
25 A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects With Severe Preeclampsia Recruiting NCT03008616 Phase 2, Phase 3
26 The Treatment of Hypertension Associated With Severe Preeclampsia. A Randomize Controlled Trial of Urapidil Versus Nicardipine. The Uranic Trial Active, not recruiting NCT02558023 Phase 3 Urapidil;Nicardipine
27 Interest of Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care: Multicentric Randomized Controlled Trial Not yet recruiting NCT03237819 Phase 3 Sulfate, Magnesium;Placebo - Concentrate
28 Investigating the Role of Early Low-dose Aspirin in Diabetes: A Phase III Multicentre Double-blinded Placebo-controlled Randomised Trial of Low-dose Aspirin Initiated in the First Trimester of Diabetes Pregnancy Not yet recruiting NCT03574909 Phase 3 Aspirin;Placebos
29 Maternal and Neonatal Outcomes After the Use of Vasopressors to Correct Hypotension During Cesarean Section Under Spinal Anesthesia in Pregnant Women With Severe Preeclampsia: Randomized Clinical Trial Withdrawn NCT01451060 Phase 3 Metaraminol;Ephedrine
30 Utility of Tocolytic Therapy for Maintenance Tocolysis in the Management of Threatened Preterm Delivery Withdrawn NCT01796522 Phase 3 progesterone 200 mg / day vaginally;nifedipine (60 mg / day orally)
31 Labetalol Versus MgSO4 for the Prevention of Eclampsia Trial (LAMPET) Withdrawn NCT00293735 Phase 2, Phase 3 labetalol (seizure prevention);MgSO4 (seizure prevention)
32 Rosuvastatin Use in Order to Induce Preeclampsia Resolution in Severe Preeclampsia Cases up to 48 Hours Following Delivery Unknown status NCT02314286 Phase 1, Phase 2 Rosuvastatin;Placebo
33 Comparison Between Dexmedetomidine and Remifentanil on the Maternal Responses to Tracheal Intubation in Severe Pre-eclamptic Patients During Caesarean Delivery Completed NCT01766089 Phase 2 Remifentanil;Dexmedetomidine
34 Sleep Disordered Breathing and Preeclampsia Completed NCT00259688 Phase 2
35 Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients at a Tertiary Care Hospital of Karachi. Completed NCT02050529 Phase 2 Labetalol;Hydralazine
36 Low-Dose Aspirin in the Postpartum Period and Endothelial Function in Patients With Preeclampsia Recruiting NCT03667326 Phase 2 Aspirin;Placebo oral capsule
37 Preeclampsia And Nonsteroidal Drugs for Analgesia (PANDA): a Randomized Non Inferiority Trial Recruiting NCT03978767 Phase 2 Ibuprofen 600 mg;Ketorolac;Acetaminophen;Oxycodone
38 Pravastatin to Prevent Preeclampsia and Reduce Maternal-Neonatal Mortality and Morbidity in High Risk Preeclampsia Patients Recruiting NCT03648970 Phase 2 Pravastatin
39 Certolizumab to Prevent Pregnancy Complications in High-Risk Patients With APS or SLE - (IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy) Recruiting NCT03152058 Phase 2 Certolizumab Pegol
40 Usefulness of Extracorporeal Removal of sFlt-1 in Women With Severe Preeclampsia at Less Than 26 Weeks' Gestation Terminated NCT02286284 Phase 2
41 Effects of Vitamin C Administration on Extravascular Lung Water in Patients With Severe Features of Preeclampsia: a Randomized, Placebo-controlled Trial Completed NCT03451266 Phase 1 Vitamin C;placebo
42 A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety of Recombinant Human Relaxin (rhRlx) in Subjects With Preeclampsia Suspended NCT00333307 Phase 1 recombinant human relaxin
43 Prognostic Value of Ambulatory Blood Pressure Monitoring Pattern in Post-Partum Pre-Eclamptic Patients Unknown status NCT02943122
44 Antiphospholipid Antibodies and Early Severe Preeclampsia (< 34 Weeks of Gestation). A Case-Control Study. Unknown status NCT01538121
45 Spinal Anesthesia in Severe Preeclampsia and Its Impact on Hemodynamics (Case Control Study) Unknown status NCT02633995
46 CA-125 and Severity of Pre-Eclampsia Unknown status NCT02704676
47 Effect of Treatment of Vitamin D Deficiency During Pregnancy on Hypocalcemia Unknown status NCT02021864 vitamin D3 50,000 unit;prenatal multivitamin
48 Random Urine Protein-creatinine Ratio to Predict Magnitude of Proteinuria in Different Severity of Pre-eclamptic Patients Unknown status NCT01623791
49 Evaluation of Kidney Injury Biomarkers in Women Suffering From Preeclampsia Unknown status NCT03217916
50 Oxidative Stress and Endothelial Function in Pregnancy Complications: Development of a New Screening Algorithm Unknown status NCT02603913

Search NIH Clinical Center for Severe Pre-Eclampsia

Genetic Tests for Severe Pre-Eclampsia

Anatomical Context for Severe Pre-Eclampsia

MalaCards organs/tissues related to Severe Pre-Eclampsia:

41
Placenta, Liver, Endothelial, Kidney, Testes, Heart, Lung

Publications for Severe Pre-Eclampsia

Articles related to Severe Pre-Eclampsia:

(show top 50) (show all 3554)
# Title Authors PMID Year
1
The 3'-untranslated region of the HLA-G gene in relation to pre-eclampsia: revisited. 9 38
20070604 2010
2
Soluble human leukocyte antigen-G isoforms in maternal plasma in early and late pregnancy. 9 38
19811467 2009
3
Is there any link between severe pre-eclampsia and defined polymorphisms in leptin and adiponectin genes? 9 38
18958929 2008
4
Antithrombin improves fetal condition in women with severe pre-eclampsia before 32 weeks of gestation; a randomized, double-blind, placebo-controlled trial. 9 38
18226126 2008
5
Effect of sera on the adhesion of natural killer cells to the endothelium in severe pre-eclampsia. 9 38
16984509 2006
6
[Expression of Fas antigen and ligand, placental growth factor in placenta of pregnant women with pre-eclampsia]. 9 38
15938782 2005
7
Maternal and fetal single nucleotide polymorphisms in the epoxide hydrolase and gluthatione S-transferase P1 genes are not associated with pre-eclampsia in the Coloured population of the Western Cape, South Africa. 9 38
16147638 2004
8
Recent progress in the therapeutic management of pre-eclampsia. 9 38
15500369 2004
9
Serum leptin levels and uterine Doppler flow velocimetry at 20 weeks' gestation as markers for the development of pre-eclampsia. 9 38
15697078 2004
10
Serum levels of leptin, insulin-like growth factor-I and insulin-like growth factor binding protein-3 in women with pre-eclampsia, and their relationship to insulin resistance. 9 38
15497497 2004
11
Serum levels of insulin, IGF-1, and IGFBP-1 in pre-eclampsia and eclampsia. 9 38
15001368 2004
12
Antinuclear antibody testing in obstetric patients. 9 38
14750494 2003
13
Factor V Leiden and prothrombin G20210A mutations in pregnancies with adverse outcome. 9 38
12572596 2002
14
Is there an increased maternal-infant prevalence of Factor V Leiden in association with severe pre-eclampsia? 9 38
11888101 2002
15
The expression and activity of monoamine oxidase A, but not of the serotonin transporter, is decreased in human placenta from pre-eclamptic pregnancies. 9 38
11133008 2000
16
Transport and metabolism of serotonin in the human placenta from normal and severely pre-eclamptic pregnancies. 9 38
10729753 2000
17
Lack of human leukocyte antigen-G expression in extravillous trophoblasts is associated with pre-eclampsia. 9 38
10611266 2000
18
Studies on the HLA-DRB1 genotypes in Japanese women with severe pre-eclampsia positive and negative for anticardiolipin antibody using a polymerase chain reaction-restriction fragment length polymorphism method. 9 38
10601082 1999
19
Vascular cell adhesion molecule-1 (VCAM-1) and leukocyte activation in pre-eclampsia and eclampsia. 9 38
9856316 1998
20
Detection of factor V Leiden mutation in severe pre-eclamptic Hungarian women. 9 38
9712539 1998
21
Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease. 9 38
8863672 1996
22
Insulin-like growth factors and their binding proteins in normal and abnormal human fetal growth. 9 38
7532055 1994
23
Lupus anticoagulant in pre-eclampsia and intra-uterine growth retardation. 9 38
1773868 1991
24
Evaluation of elabela, apelin and nitric oxide findings in maternal blood of normal pregnant women, pregnant women with pre-eclampsia, severe pre-eclampsia and umbilical arteries and venules of newborns. 38
31064239 2019
25
[Analysis of clinical early warning informations of severe preeclampsia before onset]. 38
31434428 2019
26
Asprosin in umbilical cord of newborns and maternal blood of gestational diabetes, preeclampsia, severe preeclampsia, intrauterine growth retardation and macrosemic fetus. 38
31400492 2019
27
Hepatic rupture associated with preeclampsia, report of three cases and literature review. 38
29478361 2019
28
Maternal serum AMP-activated protein kinase levels in mild and severe preeclampsia. 38
29504441 2019
29
Trends in comorbidity, acuity, and maternal risk associated with preeclampsia across obstetric volume settings. 38
29478359 2019
30
Maternal serum thrombospondin-1 is significantly altered in cases with established preeclampsia. 38
29471751 2019
31
Serum magnesium levels during magnesium sulfate infusion at 1 gram/hour versus 2 grams/hour as a maintenance dose to prevent eclampsia in women with severe preeclampsia: A randomized clinical trial. 38
31393402 2019
32
Statistical risk prediction models for adverse maternal and neonatal outcomes in severe preeclampsia in a low-resource setting: proposal for a single-centre cross-sectional study at Mpilo Central Hospital, Bulawayo, Zimbabwe. 38
31409378 2019
33
Neuropathological complications associated with hypertensive disorders of pregnancy. 38
31213115 2019
34
Optical Coherence Tomography Findings in Pre-Eclampsia: A Preliminary Receiver Operating Characteristic Analysis on Choroidal Thickness for Disease Severity. 38
30983421 2019
35
Point of care ultrasound: does the presence of ascites in severe pre-eclampsia correlate with poor maternal and neonatal outcome? 38
31173433 2019
36
lncRNA GHET1 has effects in development of pre-eclampsia. 38
30861585 2019
37
Severe maternal morbidity surveillance: Monitoring pregnant women at high risk for prolonged hospitalisation and death. 38
31407359 2019
38
Placental growth factor, vascular endothelial growth factor, and hypoxia-inducible factor-1α in the placentas of women with pre-eclampsia. 38
29455633 2019
39
Nocturnal blood pressure alterations in patients with preeclampsia - Do they really matter? A systematic review of the literature. 38
31163356 2019
40
The serum level of soluble CXCL16 is increased in preeclampsia and associated with hepatic/renal damage. 38
31257958 2019
41
Novel association of SNP rs479200 in EGLN1 gene with predisposition to preeclampsia. 38
31009679 2019
42
Fat intake during pregnancy and risk of preeclampsia: a prospective cohort study in Denmark. 38
30194370 2019
43
Maternal Height and Risk of Preeclampsia among Race/Ethnic Groups. 38
30396225 2019
44
MMP-9 and TIMP-1 in placenta of hypertensive disorder complicating pregnancy. 38
31258700 2019
45
Correlation of elevated levels of lipoprotein(a), high-density lipoprotein and low-density lipoprotein with severity of preeclampsia: a prospective longitudinal study. 38
31304822 2019
46
[Folate deficiency as a differential diagnosis to severe pre-eclampsia]. 38
31267942 2019
47
Successful management of severe preeclampsia major complications: Case report. 38
31334197 2019
48
Disturbed Cardiorespiratory Adaptation in Preeclampsia: Return to Normal Stress Regulation Shortly after Delivery? 38
31252672 2019
49
Serum CA-125 levels in preeclampsia: A systematic review and meta-analysis. 38
31162767 2019
50
Neurological manifestations and neuroimaging presentations in patients with severe preeclampsia: predisposing factors and clinical implications. 38
30891638 2019

Variations for Severe Pre-Eclampsia

Expression for Severe Pre-Eclampsia

Search GEO for disease gene expression data for Severe Pre-Eclampsia.

Pathways for Severe Pre-Eclampsia

GO Terms for Severe Pre-Eclampsia

Cellular components related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.91 VCAM1 SERPINC1 RBP4 MMP9 GPT FN1
2 extracellular space GO:0005615 9.77 VEGFA VCAM1 SERPINC1 RBP4 PGF MMP9
3 endoplasmic reticulum lumen GO:0005788 9.67 SERPINC1 FN1 F5 ALB
4 collagen-containing extracellular matrix GO:0062023 9.62 SERPINC1 MMP9 FN1 APOH
5 extracellular region GO:0005576 9.47 VEGFA SERPINC1 RBP4 PGF MMP9 LEPR
6 platelet alpha granule lumen GO:0031093 9.46 VEGFA FN1 F5 ALB

Biological processes related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.91 SERPINC1 FN1 F5 ALB
2 positive regulation of cell proliferation GO:0008284 9.91 VEGFA PGF LEP FN1 APLN
3 cytokine-mediated signaling pathway GO:0019221 9.86 VEGFA VCAM1 MMP9 FN1
4 response to ethanol GO:0045471 9.78 VCAM1 RBP4 LEP
5 glucose homeostasis GO:0042593 9.77 RBP4 LEPR LEP
6 cellular protein metabolic process GO:0044267 9.76 SERPINC1 FN1 F5 ALB
7 positive regulation of cold-induced thermogenesis GO:0120162 9.71 VEGFA LEPR LEP
8 response to nutrient GO:0007584 9.67 VCAM1 SERPINC1 LEP
9 response to hypoxia GO:0001666 9.67 VEGFA VCAM1 PGF LEP
10 leukocyte tethering or rolling GO:0050901 9.62 VCAM1 LEP
11 macrophage differentiation GO:0030225 9.6 VEGFA MMP9
12 vascular endothelial growth factor signaling pathway GO:0038084 9.58 VEGFA PGF
13 energy reserve metabolic process GO:0006112 9.58 LEPR LEP
14 induction of positive chemotaxis GO:0050930 9.57 VEGFA PGF
15 regulation of blood coagulation GO:0030193 9.55 SERPINC1 APOH
16 sexual reproduction GO:0019953 9.52 LEPR LEP
17 lactation GO:0007595 9.5 VEGFA SERPINC1 APLN
18 leptin-mediated signaling pathway GO:0033210 9.48 LEPR LEP
19 regulation of bone remodeling GO:0046850 9.43 LEPR LEP
20 positive regulation of mast cell chemotaxis GO:0060754 9.4 VEGFA PGF
21 platelet degranulation GO:0002576 9.35 VEGFA FN1 F5 APOH ALB
22 negative regulation of vasoconstriction GO:0045906 9.26 LEP APLN
23 bone growth GO:0098868 9.16 LEPR LEP
24 angiogenesis GO:0001525 9.1 VEGFA PGF LEPR LEP FN1 APLN

Molecular functions related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.56 VEGFA SERPINC1 MMP9 LEPR HLA-G FN1
2 signaling receptor binding GO:0005102 9.55 LEP HLA-G FN1 FGR APLN
3 heparin binding GO:0008201 9.02 VEGFA SERPINC1 PGF FN1 APOH

Sources for Severe Pre-Eclampsia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....